CYTOSORBENTS CORPORATION Cash and Restricted Cash
CYTOSORBENTS CORPORATION (CTSO) had Cash and Restricted Cash of $5.93 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $5.93M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $6.33M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.77M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $9.06M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $5.93M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $6.33M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $7.77M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $9.06M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $11.73M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $13.11M 10-Q · filed 2026-05-13 | $13.11M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $9.76M 10-Q · filed 2026-08-06 | $9.76M 10-K · filed 2025-03-31 |
| 2024-09-30 | $12.17M 10-Q · filed 2025-11-13 | $12.17M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $14.94M 10-Q · filed 2025-08-07 | $14.94M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $10.09M 10-Q · filed 2025-05-14 | |
| 2023-12-31 | $15.62M 10-K · filed 2026-03-30 | $15.62M 10-K · filed 2024-03-15 |
| 2023-09-30 | $10.05M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $14.84M 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $20.74M 10-Q · filed 2024-05-09 | |
| 2022-12-31 | $23.83M 10-K · filed 2025-03-31 | |
| 2022-09-30 | $24.24M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $31.85M 10-Q · filed 2023-08-01 | |
| 2022-03-31 | $44.71M 10-Q · filed 2023-05-02 | |
| 2021-12-31 | $53.83M 10-K · filed 2024-03-15 | |
| 2021-09-30 | $61.04M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $65.61M 10-Q · filed 2022-08-02 | |
| 2021-03-31 | $68.47M 10-Q · filed 2022-05-03 | |
| 2020-12-31 | $71.42M 10-K · filed 2024-03-15 | |
| 2020-09-30 | $87.98M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $35.11M 10-Q · filed 2021-08-03 | |
| 2020-03-31 | $26.39M 10-Q · filed 2021-05-04 | |
| 2019-12-31 | $12.23M 10-K · filed 2023-03-09 | |
| 2018-12-31 | $22.37M 10-K · filed 2022-03-10 | |
| 2017-12-31 | $17.32M 10-K · filed 2021-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |